Skip to content
Parakho

Orchid Pharma Ltd

NSE ORCHPHARMABSE 524372orchidpharma.com

Q1 FY27, unaudited

Revenue
₹304.17 Cr
Profit after tax
₹11.94 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations304.17+75.89%1,232.78
Other income10.05−36.93%56.49
Total income314.22+66.38%1,289.27
Employee benefit expense26.76+23.81%114.32
Finance costs2.21−32.09%8.96
Depreciation & amortisation10.90+25.97%43.36
Total expenses302.28+77.12%1,247.31
Profit before tax11.94−34.40%34.62
Tax expense0.00—0.00
Profit after tax11.94−34.40%34.62
Total comprehensive income11.94−33.80%35.94
Earnings per share
Earnings per share, basic₹1.99₹5.78
Earnings per share, diluted₹1.99₹5.78

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Orchid Pharma reported combined Q1 FY27 revenue of INR304 crores, up approximately 15% from INR263 crores a year earlier, with EBITDA improving to INR25 crores from INR10 crores in the year-ago quarter. Management attributed the improvement to gross margin recovery to about 33% and continued cost discipline, while noting the cephalosporin industry still faces overcapacity and competitive pricing. The company also gave updates on the 7-ACA and cefiderocol capital projects, the Exblifep licensing arrangement in Russia, and volume growth in Europe.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 51 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 09 Oct 2026.